Citigroup Inc. reduced its holdings in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) by 59.7% in the 4th quarter, Holdings Channel reports. The fund owned 7,609 shares of the specialty pharmaceutical company’s stock after selling 11,255 shares during the period. Citigroup Inc.’s holdings in Eagle Pharmaceuticals were worth $457,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in the stock. State Street Corp lifted its stake in Eagle Pharmaceuticals by 12.8% in the 4th quarter. State Street Corp now owns 610,591 shares of the specialty pharmaceutical company’s stock worth $36,684,000 after acquiring an additional 69,264 shares in the last quarter. Chartwell Investment Partners LLC lifted its stake in Eagle Pharmaceuticals by 0.7% in the 4th quarter. Chartwell Investment Partners LLC now owns 187,989 shares of the specialty pharmaceutical company’s stock worth $11,294,000 after acquiring an additional 1,300 shares in the last quarter. Prudential Financial Inc. lifted its stake in Eagle Pharmaceuticals by 33.4% in the 4th quarter. Prudential Financial Inc. now owns 119,231 shares of the specialty pharmaceutical company’s stock worth $7,163,000 after acquiring an additional 29,859 shares in the last quarter. Panagora Asset Management Inc. lifted its stake in Eagle Pharmaceuticals by 13.8% in the 4th quarter. Panagora Asset Management Inc. now owns 108,414 shares of the specialty pharmaceutical company’s stock worth $6,513,000 after acquiring an additional 13,168 shares in the last quarter. Finally, Principal Financial Group Inc. increased its position in Eagle Pharmaceuticals by 12.7% in the 4th quarter. Principal Financial Group Inc. now owns 89,930 shares of the specialty pharmaceutical company’s stock worth $5,403,000 after purchasing an additional 10,160 shares during the last quarter. 97.87% of the stock is owned by hedge funds and other institutional investors.
Shares of EGRX stock opened at $36.87 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.62 and a quick ratio of 4.45. Eagle Pharmaceuticals Inc has a fifty-two week low of $33.80 and a fifty-two week high of $64.94. The stock’s 50-day moving average is $47.87 and its two-hundred day moving average is $56.11. The firm has a market cap of $538.42 million, a P/E ratio of 32.00 and a beta of 1.21.
Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its earnings results on Monday, March 2nd. The specialty pharmaceutical company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.02. Eagle Pharmaceuticals had a return on equity of 9.99% and a net margin of 7.31%. The company had revenue of $48.30 million for the quarter, compared to analyst estimates of $49.08 million. During the same period in the prior year, the firm posted $1.20 EPS. The business’s revenue was down 13.8% compared to the same quarter last year. As a group, research analysts expect that Eagle Pharmaceuticals Inc will post 1.36 EPS for the current year.
Several brokerages have weighed in on EGRX. Cantor Fitzgerald dropped their target price on Eagle Pharmaceuticals from $58.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, March 2nd. ValuEngine lowered Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Zacks Investment Research lowered Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Friday, March 6th. Finally, BidaskClub raised Eagle Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $57.25.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin’s lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.
Recommended Story: Economic Bubble
Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals Inc (NASDAQ:EGRX).
Receive News & Ratings for Eagle Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.